文献速递肝病

2D/3D直接抗病毒方案治疗HCV诱导的Child-Pugh A级肝硬化的安全性——一项汇总分析

Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
PubMed 文献 · J Hepatol · 2017-06-21

本文汇总了12项II期或III期临床试验中1066例HCV感染合并Child-Pugh A级肝硬化患者,评估含奥比他韦/帕利瑞韦/利托那韦±达萨布韦±利巴韦林方案的安全性。严重治疗中出现的不良事件发生率为5.3%,导致停药的不良事件为2.2%,符合肝功能失代偿的不良事件为1.2%。结论认为该方案在此人群中安全,支持其使用。

要点

  • 1066例Child-Pugh A级肝硬化患者中,严重TEAE发生率为5.3%(95%CI 4.1-6.8)。
  • 导致研究药物停用的TEAE发生率为2.2%(95%CI 1.4-3.2)。
  • 符合肝功能失代偿的TEAE发生率为1.2%(95%CI 0.7-2.1)。

核心结论

  • 该汇总分析在1066例HCV感染合并Child-Pugh A级肝硬化患者中证实了OBV/PTV/r±DSV±RBV的安全性,结果支持在此高危人群中应用该方案。

研究设计与样本

  • 汇总了12项II期或III期临床试验,纳入完成治疗至2015年11月16日的Child-Pugh A级肝硬化患者,进行事后安全性汇总评估。

主要发现

  • 在1066例Child-Pugh A级肝硬化患者中,严重TEAE发生率为5.3%(95%CI 4.1-6.8),导致停药TEAE发生率为2.2%(95%CI 1.4-3.2)。
  • 13例患者(1.2%;95%CI 0.7-2.1)出现符合肝功能失代偿的TEAE。
  • 最常见的符合肝功能失代偿的TEAE为腹水(n=8)、食管静脉曲张出血(n=4)和肝性脑病(n=2)。

关键数值与推荐

  • 严重TEAE发生率5.3%(95%CI 4.1-6.8),导致停药TEAE发生率2.2%(95%CI 1.4-3.2),肝功能失代偿TEAE发生率1.2%(95%CI 0.7-2.1)。

临床怎么用

  • 作者认为,结果支持在Child-Pugh A级肝硬化这一高危人群中应用OBV/PTV/r±DSV±RBV方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic hepatitis C virus (HCV)-infected patients with cirrhosis are a high-priority population for treatment. To help inform the benefit-risk profile of the all-oral direct-acting antiviral (DAA) combination regimen of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir (OBV/PTV/r±DSV) in patients with Child-Pugh A cirrhosis, we undertook a comprehensive review of AbbVie-sponsored clinical trials enrolling patients with Child-Pugh A cirrhosis. METHODS: Twelve phase II or III clinical trials of the 2-DAA regimen of OBV/PTV/r±ribavirin (RBV) or the 3-DAA regimen of OBV/PTV/r+DSV±RBV that included patients with Child-Pugh A cirrhosis were reviewed; patients who completed treatment by November 16, 2015 were included in a pooled, post hoc safety assessment. The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported. RESULTS: In 1,066 patients with Child-Pugh A cirrhosis, rates of serious TEAEs and TEAEs leading to study drug discontinuation were 5.3% (95% confidence interval [CI]: 4.1-6.8) and 2.2% (95% CI: 1.4-3.2), respectively. Thirteen patients (1.2%; 95% CI: 0.7-2.1) had a TEAE that was consistent with hepatic decompensation. The most frequent TEAEs consistent with hepatic decompensation were ascites (n=8), esophageal variceal hemorrhage (n=4), and hepatic encephalopathy (n=2). CONCLUSIONS: This pooled analysis in 1,066 HCV-infected patients with Child-Pugh A cirrhosis confirms the safety of OBV/PTV/r±DSV±RBV in this population. These results support the use of OBV/PTV/r±DSV±RBV in this high-priority population. Lay summary: This pooled safety analysis in 1,066 HCV-infected patients with compensated cirrhosis, receiving treatment with ombitasvir, paritaprevir, and ritonavir with or without dasabuvir, with or without ribavirin, shows that the rate of hepatic decompensation events was similar to previously reported rates in untreated patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Poordad F, Nelson DR, Feld JJ, et al. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. J Hepatol. 2017. PMID: 28645740. doi:10.1016/j.jhep.2017.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。